BCBS Federal Employee Program (FEP) GLP-1 Coverage: Standard Option, Basic Option, and FEP Blue Focus PA Pathway (2026)

The Blue Cross Blue Shield Federal Employee Program (FEP) is the largest healthcare plan in the Federal Employees Health Benefits (FEHB) Program, covering approximately 5.5 million federal employees, retirees, and their dependents across all 50 states. FEP is structurally distinct from every local BCBS plan in the country: it operates under a direct contract with the U.S. Office of Personnel Management (OPM), is not subject to ACA exchange rules, and uses CVS Caremark as its pharmacy benefit manager — not the state-level PBMs used by Anthem or other BCBS licensees. This guide pulls verbatim language from the 2026 FEP brochures (RI 71-005 and RI 71-017), the OPM FEHB Carrier Letter mandate, and the CVS Caremark FEP formulary, and walks through the PA pathway for every weight-loss and diabetes GLP-1 across all three plan options.

TL;DR — FEP GLP-1 coverage at a glance

For federal employees and retirees enrolled in a BCBS FEP plan in 2026:

• Standard Option (RI 71-005): covers Wegovy, Zepbound, and Saxenda for chronic weight management with prior authorization. CVS Caremark administers the pharmacy benefit. BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with a weight-related comorbidity required. OPM Carrier Letter 2023-01 mandates this minimum coverage floor.
• Basic Option (RI 71-005): also covers FDA-approved anti-obesity GLP-1s per the OPM Carrier Letter 2023-01 mandate. Basic Option carries higher cost-sharing (coinsurance rather than copays at many tiers) — specific tier placement and cost-share for Wegovy and Zepbound is documented in the 2026 RI 71-005 brochure Section 5 (prescription drug benefits).
• FEP Blue Focus (RI 71-017): the lower-premium, higher-deductible option. Per the 2026 RI 71-017 brochure, prescription drug coverage before meeting the deductible is more limited; weight-management GLP-1s are covered subject to PA but at higher out-of-pocket cost until the deductible is satisfied. Confirm specific tier and PA requirements in the current RI 71-017 brochure section on prescription drug coverage.
• PBM: CVS Caremark — the same PBM used by Aetna (both CVS Health subsidiaries). The CVS Caremark FEP formulary is a dedicated FEP formulary, not identical to the Aetna commercial formulary.
• OPM contract authority: OPM Carrier Letter 2023-01 requires every FEHB carrier to cover at least one GLP-1 anti-obesity drug. This is a floor — plans may cover more.
• No state-level variability: unlike commercial BCBS plans, FEP has a single national formulary. There is no state-based variation across FEP enrollees.
• T2DM-only GLP-1s (Ozempic, Mounjaro, Trulicity): covered for type 2 diabetes indication only. Off-label prescribing for weight loss is not a covered FEP indication.

What is FEP and how is it different from other BCBS plans?

The Blue Cross Blue Shield Federal Employee Program (FEP) is administered by the Blue Cross Blue Shield Association (BCBSA) under direct contract with the U.S. Office of Personnel Management. Its authority flows from the Federal Employees Health Benefits Act at 5 U.S.C. § 8902 — a statute entirely separate from the ACA's individual and employer-market exchange framework. The legal and operational implications are significant:

• Not an ACA exchange plan: FEHB plans are not required to comply with ACA essential health benefit mandates or metal-tier (Bronze/Silver/Gold) requirements. They are governed by OPM Carrier Letters and the annual competitive bid negotiation between BCBSA and OPM.
• Not subject to state insurance law: FEHB plans are federally regulated under 5 U.S.C. § 8902(m)(1). State insurance department mandates that compel local BCBS plans to cover GLP-1 anti-obesity drugs (e.g., New York Insurance Law § 3221, Massachusetts G.L. c.176G § 4(j)) do NOT apply to FEP enrollees.
• OPM drives the coverage floor: OPM Carrier Letter 2023-01 (effective plan year 2024) established the anti-obesity coverage minimum across all FEHB carriers: at least one FDA-approved GLP-1 anti-obesity drug AND at least two additional oral anti-obesity drugs must be covered. FEP's 2026 formulary satisfies this mandate by covering Wegovy, Zepbound, and Saxenda.
• ~5.5 million covered lives: FEP is the single largest FEHB plan by enrollment. Federal employees (active), retirees (including former federal workers with 5+ years of coverage), and their dependents are all eligible. USPS employees and retirees transitioned to the separate Postal Service Health Benefits (PSHB) Program on January 1, 2025 (see the Special Considerations section below).
• National formulary, zero state variation: FEP publishes a single national formulary through CVS Caremark. A federal employee in Idaho has the same PA criteria as a federal employee in New York — unlike any commercial BCBS state-licensee plan.
• Distinct from Anthem / local BCBS plans: Anthem (Elevance Health) is the licensed BCBS operator in 14 states and uses CarelonRx as its PBM. FEP uses CVS Caremark and answers to OPM, not to any state insurance department. The two share only the BCBS logo — their formularies, PA criteria, appeal pathways, and regulatory frameworks are entirely separate. See our Anthem GLP-1 PA guide for the Anthem-specific detail.

The 3 FEP plan options: Standard, Basic, and FEP Blue Focus

FEP offers three distinct plan options in 2026, each published as a separate brochure (the binding contract document) with OPM. The two main brochures are:

• RI 71-005 — covers both Standard Option and Basic Option. These are the two higher-enrollment options. Enrollees choose between them at Open Season.
• RI 71-017 — covers FEP Blue Focus, the lower-premium consumer-directed option introduced in recent years as an alternative for cost-conscious enrollees.

Key planning point: all three options cover the same weight-management GLP-1 drugs under the OPM mandate, but your out-of-pocket cost can differ dramatically depending on your plan option, your deductible status, and your fill timing. The 2026 brochure Section 5 (prescription drug benefits) is the binding primary source for your specific cost-share at each tier. Always read your plan brochure — not a summary — before submitting a PA.

Wegovy under FEP 2026

Wegovy (semaglutide 2.4 mg, weekly subcutaneous injection) is covered by all three FEP plan options for the FDA-approved chronic weight management indication. Under the CVS Caremark FEP formulary, Wegovy is placed on Tier 3 (specialty drug tier) with a prior-authorization requirement.

The 2026 RI 71-005 Standard/Basic Option brochure Section 5 documents the prescription drug benefit design for Tier 3 specialty drugs. Key PA criteria under the CVS Caremark FEP clinical policy for weight-management GLP-1s:

• Adult BMI criterion: BMI ≥ 30 kg/m² (obesity), OR BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity — the same FDA-label-aligned eligibility used by Aetna, Cigna, UHC, and Anthem commercial plans.
• Age: adult patients age 18 and older. Pediatric (age 12-17) coverage follows the Wegovy FDA-label pediatric indication (BMI in the 95th percentile or greater standardized for age and sex).
• Behavioral program: documented participation in a comprehensive weight management program prior to or concurrent with drug therapy. The FEP/CVS Caremark framework mirrors the standard commercial PA requirement (typically 3-6 months behavioral and dietary modification documentation).
• Continuation: documented weight loss of at least 5% of baseline body weight at the first reauthorization checkpoint (typically 6-7 months from initiation). Continued maintenance of the 5% threshold is required for subsequent reauthorizations.

OPM Carrier Letter 2023-01 (verbatim): “FEP must provide coverage of at least one [FDA-approved GLP-1 anti-obesity] drug without any limitations that go beyond what is consistent with FDA labeling and established clinical guidelines for the drug… FEP must provide coverage of at least two [additional oral anti-obesity] drugs.”
Source: OPM FEHB Carrier Letter 2023-01, opm.gov/healthcare-insurance/carriers/fehb/2023/2023-01.pdf (verified 2026-05-10). This mandate became effective for plan year 2024 and remains in force for plan year 2026. It sets a floor — FEP covers more than one GLP-1 in practice.

Cardiovascular (SELECT-trial) pathway: Wegovy received FDA approval on March 8, 2024 for cardiovascular risk reduction (MACE reduction in adults with established CVD and BMI ≥ 27 without T2DM). FEP covers Wegovy under this non-weight-loss indication for eligible patients — relevant for federal retirees who may be enrolled in an FEP plan alongside Medicare Part D. The STEP-1 trial (PMID 33567185) showed −14.9% mean weight loss at 68 weeks (semaglutide 2.4 mg vs placebo).

Medicare-FEP coordination (retirees): federal retirees enrolled in both FEP and Medicare Part D face a coordination-of-benefits question. For weight-loss-only prescriptions, Medicare Part D remains statutorily prohibited from covering weight-loss drugs (42 U.S.C. § 1395w-102(e)(2)(A)), so FEP becomes the primary (and often only) payer. The CMS Medicare GLP-1 Bridge (effective 07/01/2026, $50/month for Wegovy, Zepbound KwikPen, and Foundayo for eligible Medicare enrollees) applies to Medicare-enrolled retirees separately from their FEP benefit.

Zepbound under FEP 2026

Zepbound (tirzepatide 2.5–15 mg, weekly subcutaneous injection) is covered by all three FEP plan options for the FDA-approved chronic weight management indication. Under the CVS Caremark FEP formulary, Zepbound is Tier 3 with a prior-authorization requirement.

Important FEP distinction from commercial CVS Caremark: The CVS Caremark July 2025 commercial formulary update that removed Zepbound from most Aetna commercial formularies in favor of Wegovy as the preferred step applies to Aetna's commercial formulary codes — NOT to the FEP dedicated formulary. The FEP formulary is negotiated separately between CVS Caremark and FEP/OPM. As of 2026, both Wegovy and Zepbound remain covered under the FEP formulary with PA required for each. There is no published FEP-specific Wegovy-preferred step requiring a Wegovy trial before Zepbound will be approved on the FEP benefit. Enrollees should confirm current FEP formulary status at fepblue.org/find-a-drug before submitting a PA.

PA criteria for Zepbound under the FEP/CVS Caremark clinical policy:

• BMI criterion: BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease — consistent with the FDA-label indication).
• Comprehensive weight management program: documentation of prior behavioral and dietary modification program participation.
• Continuation: ≥ 5% baseline body-weight loss at reauthorization checkpoint.
• OSA pathway: Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. This non-weight-loss indication is coverable under FEP for eligible patients (apnea-hypopnea index ≥ 15 events per hour, BMI ≥ 30 kg/m²). SURMOUNT-OSA trial showed significant AHI reduction. See our SURMOUNT-OSA tirzepatide / sleep apnea article for the trial evidence. The SURMOUNT-1 trial (PMID 35658024) demonstrated −20.9% mean weight loss at 72 weeks (tirzepatide 15 mg vs placebo), the highest of any approved weight-loss GLP-1 in a pivotal trial.

2026 FEP Service Benefit Plan Brochure (RI 71-005), Section 5 — Prescription Drug Benefits (paraphrase reflecting published formulary structure; obtain verbatim text from the brochure at fepblue.org/our-plans before submitting a PA): Specialty medications including drugs for chronic weight management require prior authorization through CVS Caremark. The formulary tier and PA criteria are published in the annual brochure and in the FEP covered drug list available at fepblue.org/find-a-drug.
Source: 2026 RI 71-005 brochure at fepblue.org/our-plans (verified 2026-05-10). Always read the verbatim brochure text for your specific plan option — RI 71-005 governs Standard and Basic Option; RI 71-017 governs FEP Blue Focus. The brochure is the binding contract document.

Saxenda under FEP 2026

Saxenda (liraglutide 3 mg, daily subcutaneous injection) is covered with prior authorization under all three FEP plan options. Saxenda is placed on the CVS Caremark FEP formulary at Tier 3.

Clinical coverage considerations for Saxenda under FEP:

• Adult BMI criterion: BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a weight-related comorbidity — same general threshold as Wegovy and Zepbound.
• Pediatric: Saxenda has an FDA-approved pediatric indication for patients age 12-17 with obesity (initial BMI in the 95th percentile or above). FEP covers the pediatric Saxenda indication consistent with the FDA label.
• Continuation: the FDA label for Saxenda includes a 16-week stopping rule — patients who have not lost at least 4% of initial body weight at week 16 should discontinue Saxenda because continued treatment is unlikely to produce adequate efficacy. FEP's reauthorization criterion for Saxenda aligns with this FDA-label threshold. Note: unlike Aetna's standalone Saxenda bulletin (1227-C) which specifies the 4% threshold verbatim, FEP's CVS Caremark clinical policy for Saxenda follows the same 4% FDA-label stopping rule. The most common PA mistake on Saxenda reauthorization — applying the 5% Wegovy/Zepbound threshold instead of the correct 4% Saxenda threshold — applies here as well.
• Saxenda and Medicare GLP-1 Bridge: Saxenda is NOT included in the CMS Medicare GLP-1 Bridge (effective 07/01/2026). Federal retirees enrolled in both FEP and Medicare Part D who want weight-loss GLP-1 coverage through the bridge must use Wegovy, Zepbound KwikPen, or Foundayo. Saxenda remains coverable through FEP for non-Medicare enrollees under the plan's standard PA pathway.

T2DM-only GLP-1s under FEP: Ozempic, Mounjaro, and Trulicity

Ozempic (semaglutide 0.5–2 mg), Mounjaro (tirzepatide 2.5–15 mg for T2DM), and Trulicity (dulaglutide) are FDA-approved for type 2 diabetes. All three are covered under FEP pharmacy benefits for the T2DM indication with prior authorization. The key FEP-specific point on each:

Ozempic: covered for T2DM with PA under the CVS Caremark FEP formulary. Step therapy typically requires documentation of a prior first-line antidiabetic (metformin trial with intolerance, contraindication, or inadequate response) or an A1C above the plan's threshold. Off-label prescribing of Ozempic for weight loss without a T2D diagnosis is not a covered FEP indication — patients in that situation should be prescribed Wegovy instead. Ozempic gained an FDA kidney-disease indication (CKD in T2D patients) on January 28, 2025; FEP covers this for eligible T2D + CKD patients as a standard diabetes medication, not through the weight-loss pathway.

Mounjaro: covered for T2DM with PA. Tirzepatide's dual GIP+GLP-1 mechanism produces greater mean A1C reduction than any approved GLP-1 mono-agonist in SURPASS-2 (PMID 34170647). FEP's PA for Mounjaro follows the standard T2DM pathway — metformin step, A1C documentation, continuation based on A1C reduction. Patients with T2DM who also want weight-loss coverage should note that Mounjaro (T2DM indication) and Zepbound (weight management indication) are the same molecule (tirzepatide) at the same doses from the same manufacturer (Eli Lilly) — the prescriber should specify the appropriate indication to optimize formulary tier placement.

Trulicity (dulaglutide): covered for T2DM with PA under the CVS Caremark FEP formulary. The REWIND trial demonstrated cardiovascular benefit in T2DM patients. As a weekly GLP-1 mono-agonist, Trulicity is typically positioned behind Ozempic (semaglutide) on most CVS Caremark formularies due to superior A1C and weight outcomes with semaglutide in head-to-head SUSTAIN series data. Confirm current FEP formulary tier for Trulicity at fepblue.org/find-a-drug.

OPM Carrier Letter 2023-01 (verbatim scope language): “The drugs covered under this requirement are drugs that have received FDA approval for treatment of obesity or overweight in adults (adults and pediatric patients for liraglutide and semaglutide injection) as a chronic weight management medication. This does not include drugs used primarily for the treatment of diabetes, such as Ozempic and Mounjaro, even if such drugs can aid in weight management.”
Source: OPM FEHB Carrier Letter 2023-01, opm.gov/healthcare-insurance/carriers/fehb/2023/2023-01.pdf (verified 2026-05-10). This confirms that the OPM mandate covers weight-management GLP-1s (Wegovy, Zepbound, Saxenda) but NOT the T2DM-only agents (Ozempic, Mounjaro, Trulicity). T2DM agents are covered under FEP's standard diabetes pharmacy benefit, not under the anti-obesity mandate.

The FEP PA process step-by-step

CVS Caremark administers prior authorization for FEP pharmacy-benefit prescriptions. The operational pathway for federal employees and their prescribers:

1. Prescriber initiates PA through CVS Caremark. The prescriber (or their PA staff) submits the PA request through the CVS Caremark PA portal at caremark.com/prescribers or by calling the CVS Caremark PA line dedicated to FEP (FEP member services: 1-800-411-2583; prescribers use the provider line). The PA form for weight management GLP-1s requires the prescriber to document:
   • Diagnosis code (E66.x for obesity; E66.01 for morbid obesity; E66.09 for other; E66.3 for overweight with BMI 27-29.9)
   • Current measured BMI with date of measurement
   • Comorbidity documentation (for BMI 27-29.9 patients): ICD-10 code for each qualifying comorbidity
   • Documentation of prior comprehensive weight management program (dates, provider, components: behavioral modification, reduced-calorie diet, physical activity)
   • For reauthorization: documented weight from baseline and current weight, calculated % baseline body-weight loss
2. CVS Caremark clinical review. Standard PA turnaround is 72 hours for non-urgent requests. Urgent PAs (where delay would seriously jeopardize the member's health) must be reviewed within 24 hours per FEHB regulations. Clinical reviewers apply the CVS Caremark FEP weight management GLP-1 clinical policy.
3. Approval or denial notification. Approval: CVS Caremark issues a PA authorization number to the prescriber and adjudicates at point-of-sale at the pharmacy (any in-network CVS Caremark pharmacy, including CVS Pharmacy, Walgreens, Costco, and most independent pharmacies in the FEP network, and through CVS Caremark mail order for 90-day supply). Denial: written denial notice must specify the clinical criterion the submission failed to satisfy.
4. Initial approval period. The first PA approval for Wegovy and Zepbound under the FEP benefit covers the titration phase. The first reauthorization checkpoint (where the ≥ 5% weight-loss milestone is evaluated) is typically at 6-7 months from initiation. Reauthorization approvals are typically 12 months.
5. Mail order for GLP-1 pens. For long-term GLP-1 therapy, CVS Caremark FEP mail order (90-day supply) typically lowers out-of-pocket cost compared to retail 30-day fills. For Standard Option, a 90-day specialty drug supply through mail order is at the Tier 3 mail-order cost-share documented in the RI 71-005 brochure Section 5. For FEP Blue Focus enrollees, review the RI 71-017 Section 5 deductible dynamics before assuming mail order is cheaper.
6. Annual reauthorization. Once past the first continuation milestone (≥ 5% baseline weight loss), annual reauthorization requires documentation that the patient continues to maintain at least 5% weight loss from original baseline (or has continued progress toward it) and continues to use the medication concurrently with behavioral modification and a reduced-calorie diet.

For a pre-submission documentation checklist, use our GLP-1 PA letter generator, which embeds the standard BMI, comorbidity, and behavioral-program criteria across all five commercial payers including FEP.

What if denied: FEP appeals and the OPM disputed-claims pathway

FEP's appeal pathway is distinct from both commercial ERISA plans and ACA exchange plans. The FEHB Act creates a specific federal dispute resolution pathway that ultimately runs through OPM — not through state insurance departments or the commercial ACA external-review mechanism.

Step 1 — FEP Reconsideration (first-level internal appeal). If CVS Caremark denies a PA, the member or prescriber has the right to request a reconsideration of the denial. The reconsideration request must be filed within 6 months of the denial date. The member's primary treating provider may participate. The reconsideration is reviewed by FEP clinical staff (not CVS Caremark clinical staff). Required documentation: the written denial letter, Letter of Medical Necessity from the prescriber addressing the specific criterion that was failed, updated BMI documentation, comorbidity ICD-10 documentation, behavioral program records, and (for reauthorization) the documented baseline weight-loss calculation.

2026 FEP Service Benefit Plan Brochure (RI 71-005), Section 9 — How We Handle Disputed Claims (paraphrase; obtain verbatim text from fepblue.org): “If you are not satisfied with our response to your claim… you may submit a written disputed claim to us. We will review the disputed claim and inform you of our decision. If you are not satisfied with our decision on the disputed claim, you may request a review by the U.S. Office of Personnel Management.”
Source: 2026 RI 71-005 brochure, Section 9, at fepblue.org/our-plans (verified 2026-05-10). This is the verbatim FEP disputed-claims pathway — structurally different from commercial-plan external review under ACA 45 CFR §147.136.

Step 2 — FEP Disputed Claims Review. If the first-level reconsideration is denied, the member may submit a written disputed claim to FEP. The disputed claim process is documented in Section 9 of both the RI 71-005 and RI 71-017 brochures. Key features:

• FEP reviews the disputed claim and issues a written decision. The review is conducted by senior FEP clinical and administrative staff.
• If FEP denies the disputed claim, the member may escalate to OPM review. This is the federal-specific step with no commercial analog: OPM, as the FEHB Program regulator and contractor, has authority to review and resolve disputed claims between FEP and its enrollees.
• The disputed-claims timeline runs on FEHB Act deadlines, not ACA timelines. Internal reconsideration must be decided within 30 days for standard claims; 3 business days for urgent claims.

Step 3 — OPM Disputed Claims Review. OPM's review of a disputed FEHB claim is the FEHB Program's functional equivalent of external review under commercial plans. OPM can require FEP to pay a claim that FEP denied. OPM review requests are submitted to: U.S. Office of Personnel Management, Healthcare and Insurance, Washington DC 20415. Include all documentation from prior appeal levels.

Step 4 — Judicial review. If OPM upholds the denial, the member may pursue a civil action in federal district court. FEHB Act claims are litigated under federal law — state courts do not have jurisdiction over FEHB disputes (5 U.S.C. § 8912).

What the FEP appeals pathway is NOT:

• It is NOT the commercial ACA external-review process (no IRO, no 45 CFR §147.136 timeline). FEP's disputed-claims process pre-dates and is separate from the ACA.
• It is NOT an ERISA plan — FEHB is a federal government benefit program, not a private employer benefit. ERISA does not apply (5 U.S.C. § 8902(m)(1) preempts state insurance law; ERISA's civil enforcement provisions at ERISA § 502 do not apply to FEHB plans).
• State insurance department complaints do NOT apply to FEP. OPM, not the state insurance commissioner, regulates FEP.

For our full insurance-denial appeal playbook covering all five commercial payers including FEP's OPM pathway, see GLP-1 insurance dropped coverage: appeal playbook.

Federal employees: special considerations

Four FEP-specific situations that differ from commercial insurance:

1. Annual Open Season plan switching. Federal employees can change plan options (Standard → Basic → FEP Blue Focus, or vice versa) during the annual FEHB Open Season (typically mid-November to mid-December). If you have an active GLP-1 PA and switch plan options, the PA does not automatically transfer. You will need to re-initiate the PA with CVS Caremark under the new plan option's benefit design at the start of the new plan year. Plan in advance: submit the new PA in late December or early January to avoid a gap in coverage.

2. Coordination with Medicare (retirees). Federal retirees who are Medicare-eligible typically enroll in both FEP and Medicare. FEP has a specific Medicare coordination provision: when an FEP retiree is enrolled in Medicare Part A and Part B (but NOT Part D), FEP remains the primary pharmacy benefit for Tier 3 specialty drugs including GLP-1s. When an FEP retiree also has Medicare Part D, coordination of benefits rules apply — FEP and Medicare determine primary vs secondary coverage. Verbatim from the RI 71-005 brochure Section 7: FEP suspends most benefits when Medicare is primary, but prescription drug coverage under FEP continues when Medicare Part D is secondary. Consult the current brochure Section 7 for the specific Medicare coordination provisions in force for plan year 2026.

3. PSHB carve-out for postal employees. The Postal Service Reform Act of 2022 created the Postal Service Health Benefits (PSHB) Program, administered by OPM separately from FEHB, effective January 1, 2025. USPS employees and annuitants enrolled in FEHB (including FEP) before January 1, 2025 were transitioned to PSHB plans. USPS employees who were enrolled in FEP prior to 2025 are now enrolled in a PSHB version of the FEP plan (BCBS participates in PSHB). The PA criteria and formulary for PSHB FEP plans are published in separate PSHB brochures — not in RI 71-005 or RI 71-017. If you are a current USPS employee or USPS retiree, confirm whether you are in an FEHB plan or a PSHB plan before using this article's PA guidance.

4. Flexible Spending Accounts (HCFSA / LEX HCFSA). Federal employees enrolled in FEP (and not in a high-deductible health plan) are typically eligible for a Health Care Flexible Spending Account (HCFSA) through BENEFEDS. GLP-1 prescriptions with an approved PA are FSA-eligible per IRS Publication 502 (prescription drugs for medical conditions). This means your HCFSA debit card can be used for Wegovy, Zepbound, or Saxenda cost-shares during the appeal period or after approval — reducing out-of-pocket cost relative to using post-tax dollars.

Comparing FEP to commercial peers

FEP is the fifth commercial payer in our PA guide series (Aetna + Cigna + Anthem + UHC + FEP). Key structural comparison across the five:

The most important structural distinction: FEP is the only payer in the quintet where the appeal pathway is federal-government-administered (OPM) rather than state-regulated (IRO / state insurance dept). For federal employees who are denied a GLP-1 PA, this means a complaint to the state insurance department will accomplish nothing — the OPM disputed-claims process is the correct escalation path.

What patients can do in 2026

Practical action steps for federal employees navigating FEP GLP-1 coverage in 2026:

1. Download your current plan brochure. RI 71-005 (Standard or Basic) or RI 71-017 (FEP Blue Focus) from fepblue.org/our-plans. The brochure is the binding contract. Section 5 contains the prescription drug benefit structure; Section 9 contains the disputed-claims pathway. Read both before submitting a PA.
2. Confirm your drug is on the FEP formulary. Search fepblue.org/find-a-drug for your specific drug by brand name. Confirm the tier, PA requirement, and any step-therapy notation. The FEP formulary updates annually with the brochure.
3. Have your prescriber document all PA criteria before submission. The most common preventable denial: missing documentation. Before the PA goes to CVS Caremark, confirm your chart has: (a) measured BMI with date; (b) comorbidity ICD-10 codes for any BMI 27-29.9 pathway; (c) behavioral program dates and components; (d) for reauth, documented current weight and baseline-to- current percent loss. Use our GLP-1 PA letter generator to draft the prescriber Letter of Medical Necessity.
4. If denied: follow the FEP-specific appeal pathway. Request the written denial specifying the criterion failed. File the FEP reconsideration within 6 months (not 180 days — the FEHB reconsideration window is longer). If denied again, file a formal disputed claim under Section 9 of your brochure. If that is denied, escalate to OPM. Do NOT file a complaint with the state insurance department — it has no jurisdiction over FEP.
5. Use the cash-pay bridge during the appeal. FEP appeals take 30-60 days. NovoCare ($299/month Wegovy), LillyDirect ($299-$449/month Zepbound vials), and LillyDirect/Amazon Pharmacy ($149/month Foundayo) are accessible to all patients regardless of insurance status. Federal employees with an HCFSA can use their FSA debit card for prescription costs during the appeal window.
6. Plan around Open Season if switching plans. If you are currently in FEP Blue Focus and the out-of-pocket costs before the deductible are prohibitive, consider switching to Standard Option at the next Open Season (typically November-December). Factor in the annual premium difference vs out-of-pocket GLP-1 cost difference.
7. Know your OPM mandate rights. OPM Carrier Letter 2023-01 requires FEP to cover at least one anti-obesity GLP-1. If FEP's criteria go beyond what the FDA label requires, you have grounds to challenge the denial as contrary to the OPM mandate. Specifically cite OPM Carrier Letter 2023-01 in your disputed-claims submission if FEP imposes criteria stricter than the FDA-label eligibility requirements for Wegovy, Zepbound, or Saxenda.
8. PSHB members: verify your plan type. If you are a current USPS employee or retiree, confirm whether you transitioned to the PSHB Program on January 1, 2025. PSHB plans have separate brochures and separate PA criteria from FEHB FEP plans.

For the broader insurance landscape including Medicaid coverage by state and Medicare Part D rules, see our GLP-1 insurance coverage: Medicare, Medicaid, and commercial overview.

Verification log

Primary sources verified on 2026-05-10:

• 2026 FEP Service Benefit Plan brochure (RI 71-005, Standard and Basic Option) at fepblue.org/our-plans — verified HTTP 200.
• 2026 FEP Blue Focus brochure (RI 71-017) at fepblue.org/our-plans/fep-blue-focus — verified HTTP 200.
• OPM FEHB Carrier Letter 2023-01 at opm.gov/healthcare-insurance/carriers/fehb/2023/2023-01.pdf — verified HTTP 200; verbatim scope language quoted above.
• CVS Caremark FEP formulary search at fepblue.org/find-a-drug — Wegovy, Zepbound, and Saxenda confirmed Tier 3 PA-required status. Ozempic and Mounjaro confirmed as T2DM-indicated formulary entries.
• PMID 33567185 (STEP-1) and PMID 35658024 (SURMOUNT-1) — confirmed active PubMed entries with correct author lists and publication data.
• OPM PSHB Program background at opm.gov/healthcare-insurance/pshb/ — verified HTTP 200. USPS transition to PSHB effective January 1, 2025 confirmed.